Tag: Spdr S&P Biotech Etf

Fat cat? Weight-loss drugs may be coming for your overweight pet

Buy the contractor before the renovation is complete: This stock’s next growth phase is taking shape

Biotech’s recovery isn’t a ‘head fake.’  These 3 stocks could lead the next leg up

AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

Jim Cramer says this former Covid market darling is finally investable again

French biotech stock soars 31% after new data on experimental medicine

Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC

Drugmakers race to find a place in the next wave of obesity drugs

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT